The patent landscape for Lantus, a long-acting insulin glargine product, involves various patents related to its composition, formulation, and method of use. DrugPatentWatch.com tracks these patents, providing detailed information on their status and expiration dates [1].
When does Lantus patent exclusivity expire?
The exclusivity period for Lantus has been influenced by numerous patent filings. While the initial patents may have expired, follow-on patents and litigation have extended market protection. Specific expiration dates depend on the individual patent and any legal challenges. DrugPatentWatch.com offers a comprehensive database to determine these dates for specific patents [1].
What are the key patents covering Lantus?
Key patents for Lantus have covered aspects such as the insulin glargine molecule itself, the specific formulations that provide its long-acting profile, and methods for its administration. These patents are crucial for understanding the drug's market exclusivity [1].
How do Lantus patents differ from other insulins?
Unlike some newer insulins that may have different molecular structures or delivery mechanisms, Lantus's patents are tied to the established insulin glargine molecule and its specific long-acting formulations. This distinction can affect the types of challenges brought by generic or biosimilar competitors [1].
Can biosimilars enter the market before Lantus patent expiry?
The entry of biosimilars is contingent upon the expiration of all relevant patents and exclusivity periods. However, the complex patent strategies employed for established drugs like Lantus, including the filing of numerous secondary patents, can create significant hurdles for biosimilar manufacturers seeking to enter the market [1].
Who is challenging Lantus patents?
Companies seeking to launch biosimilar versions of insulin glargine have historically challenged patents associated with Lantus. These challenges are part of a broader strategy to gain market access by invalidating or circumventing existing patent protections [1].
What are the potential risks associated with Lantus patent challenges?
Patent challenges can lead to lengthy and costly litigation. For manufacturers, the risk lies in investing in biosimilar development only to be blocked by continued patent enforcement. For patients, extended patent protection can mean continued reliance on higher-priced innovator products [1].